Nymox Pharmaceutical Corporation
9900 Cavendish Boulevard
St.-Laurent
Quebec
H4M 2V2
Canada
Tel: 800-936-9669
Fax: 514-332-2227
Website: http://www.nymox.com/
328 articles about Nymox Pharmaceutical Corporation
-
The Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special Meeting
11/6/2023
The Committee to Restore Nymox Shareholder Value, Inc., with a goal to recover shareholder value in Nymox Pharmaceutical Corporation, issued the following statement to Nymox shareholders regarding the special meeting of shareholders originally scheduled to be held on November 8, 2023, which it validly called in accordance with the Order of the Supreme Court, Commercial Division, of the Commonwealth of the Bahamas, filed October 5, 2023.
-
Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
10/26/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA).
-
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
9/25/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH).
-
Nymox Reports Completion of $2 Million Private Placement
8/29/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] is pleased to announce the completion of its recently reported private placement of USD 2 million.
-
Nymox Announces $2 Million Private Placement
8/2/2023
Nymox Pharmaceutical Corporation is pleased to announce an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with 500,000 warrants priced at $2.00.
-
Committee to Restore Nymox Shareholder Value Challenges Nymox CEO Averback to Publish 2022 FDA Refusal To File Correspondence Received May 10, 2022
7/27/2023
The Committee to Restore Nymox Shareholder Value, LLC, with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP, challenges the Company to publish a rarely issued Refusal to File Letter from the US Food and Drug Administration in the pursuit of full transparency and in the interests of all shareholders.
-
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
7/25/2023
Nymox Pharmaceutical Corporation [OTC: NYMXF] (the “Company”) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient NX03-0040 NYMOZARFEX (TM) U.S. study for low grade localized prostate cancer.
-
Nymox Reports on U.S. Patent Issuances
7/18/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.
-
The Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Management
7/16/2023
The Committee to Restore Nymox Shareholder Value, LLC, with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP by reestablishing a proposed partnership with a highly respected, global specialty pharmacy and healthcare solutions company, resolutely refutes all allegations made in a press release by current Nymox leadership.
-
Nymox Update
7/13/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.
-
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
7/12/2023
Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.
-
NYMOX Update - July 07, 2023
7/7/2023
Nymox Pharmaceutical Corporation is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors and the Company’s management.
-
Nymox Delisting from NASDAQ
7/5/2023
Nymox Pharmaceutical Corporation received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.
-
Nymox Provides Current Update - May 10, 2023
5/10/2023
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities.
-
Nymox Provides Corporate Update - April 03, 2023
4/3/2023
Nymox Pharmaceutical Corporation is pleased to provide a current update on the Company's ongoing projects.
-
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
3/21/2023
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox.
-
Nymox Officially Granted Extension to Regain Listing Requirements
3/15/2023
Nymox Pharmaceutical Corporation has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported.
-
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
2/15/2023
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started.
-
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
12/5/2022
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH).
-
NYMOX Provides Current Update - September 13, 2022
9/13/2022
Nymox Pharmaceutical Corporation is pleased to provide a current update on business developments.